{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:18:20Z","timestamp":1789967900025,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2943,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P50 CA097190-06"],"award-info":[{"award-number":["P50 CA097190-06"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1093\/annonc\/mdr002","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T16:58:16Z","timestamp":1299171496000},"page":"2482-2488","source":"Crossref","is-referenced-by-count":13,"title":["Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"A.","family":"Argiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Karamouzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kotsakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.F.","family":"Branstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr002_bb0010","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr002_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0020","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.2007.12.2697","article-title":"Chemoradiotherapy for locally advanced head and neck cancer","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr002_bb0030","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2004.00.1792","article-title":"Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm","volume":"24","author":"Pfister","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0035","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2007.13.3983","article-title":"Evaluation of early and late toxicities in chemoradiation trials","volume":"25","author":"Bentzen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/14737140.4.4.511","article-title":"Pemetrexed: a novel antifolate agent enters clinical practice","volume":"4","author":"Kut","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdr002_bb0045","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.ejca.2008.12.004","article-title":"C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation","volume":"45","author":"De Mattia","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr002_bb0050","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdr002_bb0055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1248\/bpb.30.839","article-title":"Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population","volume":"30","author":"Hayashi","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1093\/annonc\/mdr002_bb0060","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","article-title":"Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer","volume":"27","author":"Smit","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008571-200204000-00002","article-title":"Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses","volume":"12","author":"Urano","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1093\/annonc\/mdr002_bb0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0075","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0080","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1093\/annonc\/mdr002_bb0085","article-title":"Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): final results and correlation with TS, MTHFR and VEGF gene polymorphisms","volume":"28","author":"Argiris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1054\/bjoc.2001.2010","article-title":"Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck","volume":"85","author":"Pivot","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr002_bb0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0360-3016(03)00595-9","article-title":"Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases","volume":"57","author":"Bischof","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdr002_bb0100","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0360-3016(01)02794-8","article-title":"Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro","volume":"52","author":"Bischof","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdr002_bb0105","first-page":"833","article-title":"Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation","volume":"19","author":"Mauceri","year":"2001","journal-title":"Int J Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr002_bb0110","article-title":"Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients","volume":"26","author":"Villaflor","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-06-1058","article-title":"A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer","volume":"13","author":"Seiwert","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr002_bb0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr002_bb0125","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1055-9965.2268.13.12","article-title":"MTHFR polymorphisms and risk of chronic lymphocytic leukemia","volume":"13","author":"Rudd","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdr002_bb0130","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.ejca.2005.06.016","article-title":"Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers","volume":"41","author":"Morganti","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr002_bb0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2003.06.006","article-title":"Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer","volume":"21","author":"Vokes","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0140","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1200\/JCO.2009.27.0397","article-title":"Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer","volume":"28","author":"Cohen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0145","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JTO.0b013e3181b624ae","article-title":"Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I\/II study from the Hoosier Oncology Group","volume":"4","author":"Jalal","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr002_bb0150","article-title":"A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407\u2014early evaluation of feasibility and toxicity","volume":"26","author":"Govindan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0155","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1158\/1078-0432.CCR-03-0634","article-title":"Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck","volume":"10","author":"Milano","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr002_bb0160","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2007.13.1706","article-title":"Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer","volume":"26","author":"Seiwert","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr002_bb0165","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1200\/JCO.2006.07.9194","article-title":"Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911","volume":"25","author":"Langer","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419377178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419377178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/11\/2482\/527414\/mdr002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T13:45:13Z","timestamp":1685972713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419377178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0923753419377178"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}